Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Axcella Health is a clinical-stage biotechnology company focused on developing endogenous metabolic modulator (EMM) compositions to treat complex diseases and improve health. The company's lead programs target non-alcoholic steatohepatitis (NASH), muscle preservation in cancer, and Long COVID, utilizing amino acid-based therapies. With zero revenue, negative cash flow of $100M annually, and a market cap near zero, AXLA represents a high-risk, pre-commercial biotech dependent on clinical trial outcomes and capital raises.
Axcella operates a research-driven model focused on advancing proprietary amino acid-based compositions through clinical trials. The company aims to monetize through eventual FDA approvals and commercialization of therapies, potential licensing deals with larger pharmaceutical partners, or strategic partnerships for co-development. Current operations are funded entirely through equity raises and cash reserves. The EMM platform targets metabolic pathways, differentiating from traditional small molecule drugs, but faces typical biotech risks of clinical failure, regulatory delays, and capital intensity.
Clinical trial data readouts and milestone achievements for lead programs (NASH, Long COVID, muscle preservation)
FDA regulatory decisions including IND approvals, Fast Track designations, or breakthrough therapy status
Capital raise announcements and cash runway extensions given negative $100M annual cash flow
Strategic partnership announcements or licensing deals with larger pharmaceutical companies
Competitive clinical data from rival NASH or metabolic disease programs
Clinical trial failure risk - NASH and metabolic disease programs face high attrition rates with numerous competitive failures historically; single negative Phase 2/3 readout could render company value near zero
Capital markets dependency - with $100M annual burn and zero revenue, company requires continuous equity raises in potentially unfavorable market conditions; dilution risk exceeds 50% annually at current valuation
Regulatory pathway uncertainty for novel EMM platform - amino acid-based therapies lack established precedent, creating FDA approval timeline and endpoint definition risks
NASH competitive landscape includes well-funded programs from Madrigal, Akero, Viking Therapeutics with more advanced clinical data and larger market caps providing superior financing access
Platform technology risk - EMM approach unproven versus traditional small molecules; if mechanism fails to demonstrate efficacy, entire pipeline value collapses
Big pharma in-house metabolic programs and potential M&A of better-capitalized competitors could marginalize AXLA's strategic value
Extreme cash burn relative to market cap - current ratio of 1.21x provides minimal buffer; likely requires capital raise within 12 months based on $100M annual outflow
Debt/equity of 0.52x manageable in absolute terms but any covenant breaches or refinancing needs face challenging terms given negative cash flow profile
Going concern risk if clinical setbacks coincide with adverse capital markets - biotech funding windows can close rapidly during market stress
low - Clinical trial timelines and regulatory processes are largely insulated from GDP fluctuations. However, severe recessions can impact ability to raise capital and pharmaceutical M&A activity, which affects exit opportunities and partnership valuations. Patient enrollment may see modest impacts during economic stress.
Rising rates negatively impact AXLA through multiple channels: (1) higher discount rates compress NPV of distant future cash flows, particularly punitive for pre-revenue biotechs with 5+ year commercialization timelines, (2) reduced risk appetite among growth investors shifts capital away from speculative biotechs toward yield-generating assets, (3) increased cost of capital for future equity raises. With -428.9% ROA and complete dependence on external financing, rate environment critically affects valuation multiples and funding access.
Minimal direct credit exposure given zero revenue and no commercial operations. However, tightening credit conditions reduce availability of venture debt as bridge financing and constrain pharmaceutical partners' M&A budgets, indirectly limiting strategic exit opportunities and partnership deal flow.
growth - Attracts highly speculative biotech investors, venture capital crossover funds, and retail traders seeking asymmetric payoff from binary clinical events. Not suitable for value or income investors given zero revenue, negative earnings, and no dividend. Momentum traders may engage around data catalysts. Institutional ownership likely minimal given sub-$10M market cap and liquidity constraints.
high - Clinical-stage biotechs with single-digit million market caps exhibit extreme volatility. Stock can move 50%+ on clinical data releases, FDA communications, or financing announcements. Illiquidity amplifies price swings. Estimated beta exceeds 2.0x relative to broader biotech indices, with event-driven volatility spikes reaching 100%+ intraday.
